RecruitingPhase 2NCT05864534

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Northwestern University
Principal Investigator
Adam Sonabend, MD, MD
Northwestern University
Intervention
Balstilimab(drug)
Enrollment
25 enrolled
Eligibility
18 years · All sexes
Timeline
20242026

Study locations (1)

Collaborators

Agenus Inc. · CarThera

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05864534 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma

← Back to all trials